Clinical Scorecard: The Test That Could Save Patients' Bladders

At a Glance

Key Highlights

• 69% three-year bladder-intact survival for patients with complete clinical response.
• Detectable ctDNA before therapy indicates higher metastatic risk.
• utDNA is more sensitive than ctDNA for detecting residual bladder disease.
• Detectable utDNA correlates with shorter bladder-intact survival.
• Integration of liquid biopsy assays into routine management is supported.

Guideline-Based Recommendations

Diagnosis

• Utilize ctDNA and utDNA assays for assessing treatment response.

Management

• Consider bladder-sparing strategies for patients with complete clinical response.

Monitoring & Follow-up

• Regularly monitor ctDNA and utDNA to detect residual disease.

Risks

• Patients with detectable ctDNA or utDNA may have a higher risk of metastasis or shorter survival.

Patient & Prescribing Data

Patients with muscle-invasive bladder cancer eligible for bladder preservation.

Liquid biopsy assays can help identify candidates for bladder-sparing treatment.

Clinical Best Practices

• Incorporate liquid biopsy results into clinical decision-making.
• Monitor both ctDNA and utDNA for comprehensive disease assessment.
• Educate patients on the implications of ctDNA and utDNA findings.

References

• Proceedings of the National Academy of Sciences